Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.48 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15307782 | 1.00 | MME (0.48) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL18098146 | 1.00 | MME (0.48) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL7362168 | 0.95 | MME (0.52) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL7725288 | 0.95 | MME (0.52) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL9652457 | 0.95 | MME (0.52) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL23142756 | 0.83 | MME (0.47) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL22475286 | 0.83 | MME (0.47) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL291483 | 0.83 | MME (0.47) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL22342125 | 0.83 | MME (0.47) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL21030512 | 0.83 | MME (0.47) | MMEACECPA1ACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-20130252883-A1 | Macrocycles and Their Uses | NOVARTIS AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-8476224-B2 | Macrocycles and their uses | NOVARTIS AG (US) | 2013-07-02 | — | — | US | disclosed |
| US-20090186830-A1 | MACROCYCLES AND THEIR USES | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252883-A1 | Macrocycles and Their Uses | MRPL21, CLPP, MLEC | MME 388/4885ACE 173/4885CPA1 2497/4885 |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, HTRA2 | MME 521/4885ACE 643/4885CPA1 440/4885 |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | MME 693/4885ACE 827/4885CPA1 651/4885 |
| US-20090186830-A1 | MACROCYCLES AND THEIR USES | CYP11B2, OAT, CYP27A1 | MME 1288/4885ACE 223/4885CPA1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.